Comprehensive clinical evaluation of phosphate-lowering drugs in the treatment of chronic kidney disease with hyperphosphatemia

LIU Lu; SONG Cangsang; LI Xingde; HAN Chunni; SUN Run; YU Chunjie; LI Yalin

doi:10.6039/j.issn.1001-0408.2026.14.20

您当前的位置：

首页 >

文章列表页 >

Comprehensive clinical evaluation of phosphate-lowering drugs in the treatment of chronic kidney disease with hyperphosphatemia

更新时间：2026-07-28

- Comprehensive clinical evaluation of phosphate-lowering drugs in the treatment of chronic kidney disease with hyperphosphatemia
- ZHONGGUO YAOFANG Vol. 37, Issue 14, Pages: 1918-1924(2026)
- 作者机构：
  
  昆明市第一人民医院药学部，昆明　650224
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2026.14.20
  CLC： R969;R692
- Received：16 March 2026，
  
  Revised：2026-05-18，
  
  Accepted：08 July 2026，
  
  Online First：24 July 2026，
  
  Published：30 July 2026
- 稿件说明：
移动端阅览
刘璐,宋沧桑,李兴德,等.治疗慢性肾脏病伴高磷血症的降磷类药物临床综合评价 [J].中国药房,2026,37(14):1918-1924.

LIU Lu,SONG Cangsang,LI Xingde,et al.Comprehensive clinical evaluation of phosphate-lowering drugs in the treatment of chronic kidney disease with hyperphosphatemia[J].ZHONGGUO YAOFANG,2026,37(14):1918-1924.
刘璐,宋沧桑,李兴德,等.治疗慢性肾脏病伴高磷血症的降磷类药物临床综合评价 [J].中国药房,2026,37(14):1918-1924. DOI： 10.6039/j.issn.1001-0408.2026.14.20.

LIU Lu,SONG Cangsang,LI Xingde,et al.Comprehensive clinical evaluation of phosphate-lowering drugs in the treatment of chronic kidney disease with hyperphosphatemia[J].ZHONGGUO YAOFANG,2026,37(14):1918-1924. DOI： 10.6039/j.issn.1001-0408.2026.14.20.

摘要

目的

对降磷类药物治疗慢性肾脏病（CKD）伴高磷血症开展药品临床综合评价，为临床用药提供决策依据。

方法

检索符合纳排标准的相关研究，基于已有研究结果开展有效性、安全性、经济性综合评价，从填补临床空白等3个方面分析创新性，从技术适宜性等2个方面评估适宜性，并结合昆明37家医疗机构调研数据与医保、集采信息分析可及性。

结果

共纳入10篇Meta分析和2篇药物经济学研究：有效性上，3类降磷药（含钙磷结合剂、非含钙磷结合剂、钠/氢交换体3抑制剂）均可有效降低血磷；含钙磷结合剂升血钙更明显，司维拉姆降全段甲状旁腺激素效果优于含钙磷结合剂，含铁磷结合剂可改善铁代谢与贫血相关指标；安全性上，含铁磷结合剂胃肠道不良反应发生率最高，碳酸镧略低；经济性上，司维拉姆比含钙磷结合剂、碳酸镧更具经济优势。创新性上，非含钙磷结合剂弥补了含钙磷结合剂易诱发高钙血症的不足，含铁磷结合剂满足合并缺铁性贫血患者的需求，替那帕诺降磷机制具有创新性。适宜性上，3类降磷药各方面均有较好的适宜性。可及性上，司维拉姆的医疗机构配备率最高，替那帕诺暂无配备；3类药物均已纳入医保，碳酸镧与司维拉姆集采后价格下降，可负担性提升。

结论

CKD伴高磷血症优选非含钙磷结合剂，其中优先推荐司维拉姆；胃肠道不耐受者可选用碳酸镧，合并缺铁性贫血者优先选用含铁磷结合剂，传统方案控制不佳或不耐受者可选用替那帕诺，不推荐含钙磷结合剂作为长期用药首选。

Abstract

OBJECTIVE

To conduct a comprehensive clinical evaluation of phosphate-lowering drugs in the treatment of chronic kidney disease （CKD） with hyperphosphatemia， and to provide evidence-based support for clinical drug decision-making.

METHODS

Relevant studies meeting the inclusion and exclusion criteria were retrieved， a comprehensive evaluation of efficacy， safety and economics was conducted based on existing study results. Innovation was analyzed from three aspects including filling the clinical gap， and suitability was assessed from two aspects including technical suitability. Accessibility was evaluated based on the survey data from 37 medical institutions in Kunming， combined with information from the

National Reimbursement Drug List

and national centralized drug procurement.

RESULTS

A total of 10 meta-analyses and 2 pharmacoeconomic studies were included. In terms of efficacy， all three categories of phosphate-lowering drugs （calcium-based phosphate binders， non-calcium-based phosphate binders， sodium-hydrogen exchanger 3 inhibitors） effectively reduced serum phosphorus levels. Calcium-based phosphate binders elevated serum calcium levels more significantly； sevelamer was superior to calcium-based phosphate binders in reducing intact parathyroid hormone levels； iron-based phosphate binders improved iron metabolism and anemia-related indicators. In terms of safety， iron-based phosphate binders had the highest incidence of gastrointestinal adverse reactions， followed by lanthanum carbonate. In terms of economics， sevelamer demonstrated economic advantages over calcium-based phosphate binders and lanthanum carbonate. In terms of innovation， non-ca

lcium-based phosphate binders addressed the clinical limitation of hypercalcemia associated with calcium-based phosphate binders； iron-based phosphate binders met the treatment needs of patients with comorbid iron deficiency anemia； tenapanor exhibited an innovative phosphorus-lowering mechanism. In terms of suitability， all three categories showed good suitability in various aspects. In terms of accessibility， sevelamer had the highest availability rate， while tenapanor was not yet available in medical institutions. All three categories have been included in the

National Reimbursement Drug List

； the prices of lanthanum carbonate and sevelamer decreased substantially following centralized procurement with improved affordability.

CONCLUSIONS

For CKD patients with hyperphosphatemia， non-calcium-based phosphate binders are preferred， among which sevelamer is recommended as the first-line choice. Lanthanum carbonate may be considered for patients with gastrointestinal intolerance； iron-based phosphate binders are preferred for patients with comorbid iron deficiency anemia； tenapanor may be considered for patients with poor response to or intolerance of conventional regimens； calcium-based phosphate binders are not recommended as long-term first-line therapy.

关键词

Keywords

references

Zhou C ， Shi Z Y ， Ouyang N ， et al . Hyperphosphatemia and cardiovascular disease [J ] . Front Cell Dev Biol ， 2021 ， 9 ： 644363 .

Shaman A M ， Kowalski S R . Hyperphosphatemia management in patients with chronic kidney disease [J ] . Saudi Pharm J ， 2016 ， 24 （ 4 ）： 494 - 505 .

Dube P ， DeRiso A ， Patel M ， et al . Vascular calcification in chronic kidney disease：diversity in the vessel wall [J ] . Biomedicines ， 2021 ， 9 （ 4 ）： 404 .

Rout P ， Jialal I . Hyperphosphatemia [M ] . Treasure Island ： StatPearls Publishing ， 2025 ： 32644592 .

Vikrant S ， Parashar A . Prevalence and severity of dis-ordered mineral metabolism in patients with chronic kidney disease：a study from a tertiary care hospital in India [J ] . Indian J Endocrinol Metab ， 2016 ， 20 （ 4 ）： 460 - 467 .

Rabbani S A ， Sathvik B S ， Rao P G ， et al . Hyperphosphatemia in end stage renal disease：prevalence and patients characteristics of multiethnic population of united Arab emirates [J ] . Int J Pharm Pharm Sci ， 2017 ， 9 （ 12 ）： 283 .

Rastogi A ， Bhatt N ， Rossetti S ， et al . Management of hyperphosphatemia in end-stage renal disease：a new paradigm [J ] . J Ren Nutr ， 2021 ， 31 （ 1 ）： 21 - 34 .

国家卫生健康委药政司 . 关于药品临床综合评价管理指南公开征求意见的公告 [EB/OL ] .（ 2020-11-04 ）[ 2026-05-15 ] . https：//www.nhc.gov.cn/yaozs/c100098/202011/6fe336283f69438e9b46f090bc2ec6d1.shtml https://www.nhc.gov.cn/yaozs/c100098/202011/6fe336283f69438e9b46f090bc2ec6d1.shtml .

Ketteler M ， Block G A ， Evenepoel P ， et al . Executive summary of the 2017 KDIGO chronic kidney disease-mineral and bone disorder （CKD-MBD）guideline update：what’s changed and why it matters [J ] . Kidney Int ， 2017 ， 92 （ 6 ）： 1558 .

Shea B J ， Reeves B C ， Wells G ， et al . AMSTAR 2：a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions，or both [J ] . BMJ ， 2017 ， 358 ： j4008 .

张方圆，沈傲梅，曾宪涛，等 . 系统评价方法学质量评价工具AMSTAR 2解读 [J ] . 中国循证心血管医学杂志， 2018 ， 10 （ 1 ）： 14 - 18 .

HUTTON B ， SALANTI G ， CALDWELL D M ， et al . The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions：checklist and explanations [J ] . Ann Intern Med ， 2015 ， 162 （ 11 ）： 777 - 784 .

Husereau D ， Drummond M ， Augustovski F ， et al . Consolidated health economic evaluation reporting standards （CHEERS） 2022 explanation and elaboration：a report of the ISPOR CHEERS Ⅱ good practices task force [J ] . Value Heal ， 2022 ， 25 （ 1 ）： 10 - 31 .

World Health Organization ， Health Action International . Measuring medicine prices，availability，affordability and price components [M ] . 2nd ed . Geneva ： World Health Organization ， 2008 ： 111 - 118 .

国家医疗保障局 . 国家基本医疗保险、工伤保险和生育保险药品目录：2025 年[EB/OL ] . （ 2025-12-05 ）[ 2026-05-14 ] . https：//www.gov.cn/zhengce/zhengceku/202512/content_7050533.htm https://www.gov.cn/zhengce/zhengceku/202512/content_7050533.htm .

王珊珊 . 枸橼酸铁治疗慢性肾脏病高磷血症疗效及安全性的Meta分析 [D ] . 广州：暨南大学， 2021 ： 1 - 35 .

刘传娇，张磊，王亿平 . 荟萃分析蔗糖羟基氧化铁治疗透析患者高磷血症和肾性贫血的有效性和安全性 [J ] . 武汉大学学报（医学版）， 2025 ， 46 （ 8 ）： 1068 - 1077 .

Ding X Y ， Sun S J ， Zhang J J ， et al . Ferric citrate for the treatment of hyperphosphatemia and iron deficiency anaemia in patients with NDD-CKD：a systematic review and meta-analysis [J ] . Front Pharmacol ， 2024 ， 15 ： 1285012 .

Li L ， Zheng X ， Deng J ， et al . Ferric citrate for the treatment of hyperphosphatemia and anemia in patients with chronic kidney disease：a meta-analysis of randomized clinical trials [J ] . Ren Fail ， 2022 ， 44 （ 1 ）： 1112 - 1122 .

Zeng Q ， Zhong Y L ， Yu X Q . Meta-analysis of the efficacy and safety of sevelamer as hyperphosphatemia therapy for hemodialysis patients [J ] . Ren Fail ， 2023 ， 45 （ 1 ）： 2210230 .

Zhao L J ， Liu A ， Xu G S . Safety and effectiveness of lanthanum carbonate for hyperphosphatemia in chronic kidney disease （CKD）patients：a meta-analysis [J ] . Ren Fail ， 2021 ， 43 （ 1 ）： 1378 - 1393 .

罗孟捷，刘雅诗，李萍萍，等 . 磷结合剂治疗慢性肾脏病透析患者高磷血症的网状Meta分析 [J ] . 中国新药杂志， 2024 ， 33 （ 24 ）： 2628 - 2636 .

王运 . Tenapanor治疗维持性透析患者高磷血症的有效性及安全性的Meta分析 [D ] . 南昌：南昌大学， 2023 ： 1 - 55 .

Luo H L ， Feng J ， Zhang Y B ， et al . Efficacy and safety of tenapanor in hemodialysis patients with hyperphosphatemia：a systematic review and meta-analysis of randomized placebo-controlled trials [J ] . Ther Apher Dial ， 2023 ， 27 （ 5 ）： 839 - 847 .

Abo Elnaga A A ， Serag I ， Alsaied M A ， et al . Efficacy and safety of tenapanor vs placebo in treating CKD patients on dialysis and with hyperphosphatemia：a systematic review and meta-analysis of 2251 patients [J ] . Int Urol Nephrol ， 2025 ， 57 （ 6 ）： 1835 - 1850 .

刘国强，杨警囡 . 司维拉姆治疗慢性肾脏病高磷血症的药物经济学系统评价 [J ] . 中国药物经济学， 2021 ， 16 （ 6 ）： 26 - 30，38 .

Yang L ， Tan S ， Chen C ， et al . Cost-minimization analysis between sevelamer and lanthanum in treating hyperphosphatemia among patients with end-stage renal disease in China [J ] . J Heal Med Econ ， 2016 ， 2 （ 1 ）： 4 .

Chaiyakittisopon K ， Pattanaprateep O ， Ruenroengbun N ， et al . Evaluation of the cost-utility of phosphate binders as a treatment option for hyperphosphatemia in chronic kidney disease patients：a systematic review and meta-analysis of the economic evaluations [J ] . Eur J Heal Econ ， 2021 ， 22 （ 4 ）： 571 - 584 .

Jamal S A ， Vandermeer B ， Raggi P ， et al . Effect of calcium-based versus non-calcium-based phosphate bin-ders on mortality in patients with chronic kidney disease：an updated systematic review and meta-analysis [J ] . Lancet ， 2013 ， 382 （ 9900 ）： 1268 - 1277 .

Fishbane S ， Block G A ， Loram L ， et al . Effects of ferric citrate in patients with nondialysis-dependent CKD and iron deficiency anemia [J ] . J Am Soc Nephrol ， 2017 ， 28 （ 6 ）： 1851 - 1858 .

Yokoyama K ， Hirakata H ， Akiba T ， et al . Effect of oral JTT-751 （ferric citrate）on hyperphosphatemia in hemodialy-sis patients：results of a randomized，double-blind，placebo-controlled trial [J ] . Am J Nephrol ， 2012 ， 36 （ 5 ）： 478 - 487 .

Block G A ， Fishbane S ， Rodriguez M ， et al . A 12-week，double-blind，placebo-controlled trial of ferric citrate for the treatment of iron deficiency anemia and reduction of serum phosphate in patients with CKD stages 3-5 [J ] . Am J Kidney Dis ， 2015 ， 65 （ 5 ）： 728 - 736 .

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Analysis of influencing factors affecting the efficacy of Shenfukang capsule in the treatment of chronic kidney disease and construction of prediction model

Study on the mechanism of cordycepin inhibiting ferroptosis via the Nrf2/HO-1 pathway to delay the transformation from AKI to CKD

氢氧化镧对大鼠慢性肾衰高磷血症的改善作用研究

碳酸镧治疗尿毒症维持性血液透析患者高磷血症的临床观察

碳酸司维拉姆联合常规治疗对慢性肾衰竭合并高磷血症患者血清炎症因子及HO-1、iPTH水平的影响

Related Author

ZHONG Xiaobin

LIANG Zhiwei

ZOU Xiaoqin

YANG Yufang

QIN Mengyuan

TANG Li

ZHOU Xiaoshuang

ZHAO Zhibo

Related Institution

Dept. of Pharmacy， Guangxi Medical University Cancer Hospital

Dept. of Pharmacy， the First Affiliated Hospital of Guangxi Medical University

Dept. of Scientific Research， The First Affiliated Hospital of Guangxi Medical University

The Third Clinical College，Shanxi University of Chinese Medicine

Dept. of Nephrology，Shanxi Provincial People’s Hospital

⁰